

Press Release

Spinco Biotech Announces Marketing Partnership with Mesoscale Discovery, a division of Meso Scale Diagnostics, LLC. USA

Spinco Biotech is pleased to announce the signing of an exclusive marketing partnership with Mesoscale Discovery, USA, pioneers of a unique multiplex immunoassay platform setting the standards for accurate and precise determination of biomolecules.

Providing unparalleled sensitivity and dynamic range, the MSD instruments use the proprietary Multi-Array technology to address applications requiring high information content and high throughput. MSD offers instruments to fit every application, budget and research environment. The SECTOR S 600 is ideal for applications requiring high information content and high throughput while the MESO QuickPlex SQ 120 is a compact, affordable multiplexing imager with exceptional performance.

Supporting these systems, the MSD product line includes a diverse menu of single-PLEX and multiplex assay kits for profiling biomarkers, cell signalling pathways and other applications as well as a suite of plates and reagents for assay development. Whether one is multiplexing biomarker and cytokine assays, testing for immunogenicity or toxicity, or developing unique assays, one will appreciate the fast, simple assay processing, low sample volume requirements, and minimal consumption of reagents that this advanced technology makes possible.

Meso Scale Diagnostics, LLC., based in Rockville, Maryland, develops, manufactures, and markets instruments and assays for array-based biological measurements for research use in life sciences. MSD is the world's leading provider of highly sensitive multiplex immunoassays.

More information about MSD and its products can be found at www.mesoscale.com.